IchihashiSHigashiuraWItohH. Long-term outcomes for systematic
primary stent placement in complex iliac artery occlusive disease classified
according to Trans-Atlantic Inter-Society Consensus
(TASC)-II. J Vasc Surg.
2011;53:992–999.
2.
StockxLPoncyljuszWKrzanowskiM. Express LD vascular stent in the
treatment of iliac artery lesions: 24-month results from the MELODIE
trial. J Endovasc Ther.
2010;17:633–641.
3.
ArmstrongEJSinghSSinghGD. Angiographic characteristics of
femoropopliteal in-stent restenosis: association with long-term outcomes
after endovascular intervention. Catheter Cardiovasc
Interv. 2013 Apr 30. [Epub ahead of print]
4.
RogersJHLairdJR.
Overview of new technologies for lower extremity
revascularization. Circulation.
2007;116:2072–2085.
5.
ScheinertDScheinertSSaxJ. Prevalence and clinical impact of
stent fractures after femoropopliteal stenting. J Am
Coll Cardiol.
2005;45:312–315.
6.
LairdJRKatzenBTScheinertD. Nitinol stent implantation versus
balloon angioplasty for lesions in the superficial femoral artery and
proximal popliteal artery: twelve-month results from the RESILIENT
randomized trial. Circ Cardiovasc Interv.
2010;3:267–276.
7.
LairdJRKatzenBTScheinertD. Nitinol stent implantation vs.
balloon angioplasty for lesions in the superficial femoral and proximal
popliteal arteries of patients with claudication: three-year follow-up from
the RESILIENT randomized trial. J Endovasc
Ther.
2012;19:1–9.
8.
BosiersMDelooseKCallaertJ. Results of the Protégé
EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal
lesions. J Vasc Surg.
2011;54:1042–1050.
9.
ScheinertDGrummtLPiorkowskiM. A novel self-expanding interwoven
nitinol stent for complex femoropopliteal lesions: 24-month results of the
SUPERA SFA registry. J Endovasc Ther.
2011;18:745–752.
10.
SchulteKLKraljIGisslerHM. MISAGO 2: one-year outcomes after
implantation of the Misago self-expanding nitinol stent in the superficial
femoral and popliteal arteries of 744 patients. J
Endovasc Ther.
2012;19:774–784.
11.
MatsumuraJSYamanouchiDGoldsteinJA. The United States study for
evaluating endovascular treatments of lesions in the superficial femoral
artery and proximal popliteal artery by using the Protégé
Everflex Nitinol Stent System II (DURABILITY II). J
Vasc Surg.
2013;58:73–83.
12.
VardiMNovackVPencinaMJ. Safety and efficacy metrics for
primary nitinol stenting in femoropopliteal occlusive disease: a
meta-analysis and critical examination of current
methodologies. Catheter Cardiovasc Interv.
2013 Sep 2. [Epub ahead of print]
13.
WernerMPiorkowskiMThiemeM. SUMMIT registry: one-year outcomes
after implantation of the EPIC self-expanding nitinol stent in the
femoropopliteal segment. J Endovasc Ther.
2013;20:759–766.
14.
SafleyDMHouseJALasterSB. Quantifying improvement in symptoms,
functioning, and quality of life after peripheral endovascular
revascularization. Circulation.
2007;115:569–575.
15.
PiorkowskiMFreitasBSchmidtA. The use of the GORE TIGRIS Vascular
Stent with dual component design in the superficial femoral and popliteal
arteries at 6 months. J Cardiovasc Surg
(Torino).
2013;54:447–453.
16.
ScheinertDWernerMScheinertS. Treatment of complex atherosclerotic
popliteal artery disease with a new self-expanding interwoven nitinol
stent. JACC Cardiovasc Interv.
2013;6:65–71.
17.
LammerJZellerTHauseggerKA. Heparin-bonded covered stents versus
bare metal stents for complex femoro-popliteal artery lesions: the
randomized VIASTAR trial. J Am Coll
Cardiol. 2013 Jul 3. [Epub ahead of print]
18.
DakeMDAnselGMJaffMR. Paclitaxeleluting stents show
superiority to balloon angioplasty and bare metal stents in femoropopliteal
disease: twelve-month Zilver PTX randomized study results.
Circ Cardiovasc Interv.
2011;4:495–504.
19.
WerkMMAlbrechtTTMeyerD. Paclitaxel-coated balloons reduce
restenosis after femoro-popliteal angioplasty: evidence from the randomized
PACIFIER trial. Circ Cardiovasc Interv.
2012;5:831–840.
